Legal status · United Kingdom
Is Plecanatide legal in the United Kingdom?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Plecanatide is not an approved medicine in the United Kingdom; its classification is "Not licensed". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Plecanatide in the United Kingdom at a glance
| Classification | Not licensed |
|---|---|
| Note | No UK marketing authorisation identified as of this review. Linaclotide is the guanylate cyclase-C agonist licensed in this market. |
| MHRA approval status | Not approved by MHRA |
| Human studies cited | 2 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Plecanatide profile, checked against Medicines and Healthcare products Regulatory Agency (MHRA) listings at the reviewed date.
What this means
- 01
No product containing Plecanatide is approved by MHRA for any use in the United Kingdom, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United Kingdom. This page is general information, not legal advice.
What Plecanatide is
An oral 16-amino-acid uroguanylin analogue approved in 2017 for chronic idiopathic constipation and irritable bowel syndrome with constipation. In its pivotal phase 3, 20.1 percent of patients on 3 mg were durable responders versus 12.8 percent on placebo, a 7.3 point absolute difference. Its claimed tolerability advantage over linaclotide has never been tested head to head.
Plecanatide is a 16-amino-acid peptide that differs from human uroguanylin, the body's own guanylate cyclase-C ligand, by a single amino acid. The FDA approved it on 19 January 2017 under NDA 208745 for chronic idiopathic constipation in adults, and later for irritable bowel syndrome with constipation.
Mechanism: Agonism at guanylate cyclase-C on the luminal surface of intestinal epithelial cells. Receptor activation raises intracellular cyclic GMP, which activates the cystic fibrosis transmembrane conductance regulator and drives chloride and bicarbonate into the gut lumen, pulling water with them.
Regulatory history: FDA-approved on 19 January 2017 under NDA 208745, marketed as Trulance, for chronic idiopathic constipation and for irritable bowel syndrome with constipation in adults. Contraindicated in patients under six years of age because of the risk of serious dehydration, and its use is avoided in children aged six to under 18. Not approved for weight loss, for gut permeability or leaky gut, or for any general digestive health use.
How MHRA treats this kind of product
Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.
The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Plecanatide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Plecanatide in other countries
Frequently asked questions
Is Plecanatide legal in the United Kingdom?
No. Plecanatide is not an approved medicine in the United Kingdom; its classification is "Not licensed". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 2 human studies are cited on its profile. Note: No UK marketing authorisation identified as of this review. Linaclotide is the guanylate cyclase-C agonist licensed in this market.
Can I buy Plecanatide in the United Kingdom?
No approved product exists to buy. In the United Kingdom Plecanatide is classified as "Not licensed", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: No UK marketing authorisation identified as of this review. Linaclotide is the guanylate cyclase-C agonist licensed in this market.
Is Plecanatide MHRA approved?
No. In the United Kingdom Plecanatide is classified as "Not licensed", which is not a MHRA marketing approval. For comparison, the US FDA status is: FDA-approved on 19 January 2017 under NDA 208745, marketed as Trulance, for chronic idiopathic constipation and for irritable bowel syndrome with constipation in adults. Contraindicated in patients under six years of age because of the risk of serious dehydration, and its use is avoided in children aged six to under 18. Not approved for weight loss, for gut permeability or leaky gut, or for any general digestive health use.. On the evidence, 2 human studies are cited on its profile.
Related compounds in the United Kingdom
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Plecanatide live on its compound profile.
Plecanatide profileThis page is general information about the regulatory status of Plecanatide in the United Kingdom, current as of Sep 2026. It is not legal advice, and classifications change; check Medicines and Healthcare products Regulatory Agency directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.